

But it's MY Body: Breast Cancer Risks and Decision Making

March 26, 2018

Holly J. Pederson MD

Director, Medical Breast Services, Cleveland Clinic

Associate Professor CCLCM

Conflict of Interest

 Dr. Pederson serves as a consultant for Myriad Genetics, Inc.

Practice of Clinical Cancer Genetics

- When faced with a patient with cancer:
 - Is it heritable?
 - Is is sporadic?
- Implications for patient
 - Which cancer(s) is this patient at risk for?
 - At what ages do these risks rise?
 - What to do for the patient?
- Implications for patient's family
 - Who are at risk for cancer?
 - What to do for each family member?



The Story of Rachel Cowden (ca 1960's)

- Rachel Cowden Died at 33 Years of Age
 - Metastatic Breast Cancer
 - □ Population Average Age at Diagnosis of Breast Cancer: 60 Years Old
- Ms Cowden also had Unusual Skin Findings, Thyroid Neoplasias, etc
 - □ No doctor knew what she had (1963)
- •The New Disorder was Named in Honor of Rachel Cowden (by Lloyd & Denis, Ann Intern Med 1963)
 - □Cowden Syndrome



PTEN- Associated Age-Related Cancer Risks Help Guide Management

Cancer	General population risk	Lifetime Risk in CS with <i>PTEN</i> mutation
Breast	12%	85%
Thyroid	1%	35%
Endometrial	2.6%	28%
Renal cell	1.6%	34%
Colon	5%	9%
Melanoma	2%	6%

PTEN mutations Increase the Risk of Early-Onset Breast Cancer

	By age 50	Lifetime Risk
Population Risk	2%	7-12%
Hereditary Risk	Up to 50%	67-85%





Tan et al. Clin Cancer Res 2012; 18(2): 400-407 Bubien V et al. J Med Genet 2013; 50(4): 255-63 Nieuwenhuis MH et al. Fam Cancer 2013; 13(1): 1818-24

Breast cancer is often diagnosed again




Fig 2. Cumulative risk of breast second malignant neoplasm after first breast cancer in patients with PTEN hamartoma tumor syndromes.

Current NCCN Guidelines for PHTS Breast Management

- Breast awareness starting at age 18 y
- Clinical breast exam every 6-12 months, starting at age 25, or 5-10 years before the earliest known breast cancer in the family
- Annual mammography with consideration of tomosynthesis and breast MRI screening starting at age 30-35 until age 75
- Consider risk-reducing mastectomy

Why MRI? More DCIS and smaller node negative cancers


- Prospective, not randomized
- 445 mammo + MRI
- 830 mammo only
- Mean F/U: 3 years

Type of cancer	HR
	(+MRI)
DCIS	1.71
Invasive cancer	0.79
< 2cm, LN-	1.33
> 2 cm , LN+	0.30
	P=0.008

Warner et al. JCO 2011; 29: 1664-1669.

What about Digital Breast Tomosynthesis – 3D mammography?

- Density can mask tumors
- 25-40%improvedsensitivity
- 15% fewer false positives
- No data specifically in PTEN carriers



Friedewald et al. JAMA 2014; 311: 2499-2507

Risk Reducing Mastectomy

OCCULT BREAST CANCER RISK: ~3%



Consider skin-sparing, nipple-sparing bilateral risk-reducing mastectomy



1. Domchek SM, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. JAMA. 2010;304(9):967-975.

2. Hartmann LC, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. JNCI. 2001;93:1633-1637. 3. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. v2.2017. Available at http://www.nccn.org.

Nipple Sparing Mastectomy with Reconstruction





Cleveland Clinic – courtesy of Dr. Risal Djohan

Rachel Cowden in the 21st Century

Genetics Evaluation

- Personal & Family Health History Taking
- Diagnoses
 Considered

Genetic Counseling

- Information on Genetics
- Education re: Gene Testing

Blood Drawn

 PTEN Gene Testing

PTEN Test Results Returned

 With Post-Test Genetic Counseling

PTEN-Directed Risk Management

- Breast, Thyroid, Uterus, Kidney, Colon
- Multi-Care Team

Ms. Cowden may not have died of breast cancer that young.



In conclusion:

All women deserve to receive the information needed to allow themselves to make decisions that they believe are in their best interest.



Cleveland Clinic

Every life deserves world class care.